

February 22, 2006

AnGes MG, Inc.

**AnGes MG, Inc. Announced Preliminary Results of the US Phase II Clinical
Trial with HGF Gene Therapy for PAD (Peripheral Arterial Disease)**

On 2/22/2006, AnGes MG, Inc. announced that the US Phase II PAD clinical trial with HGF gene therapy had been unblinded.

This is an exploratory, Phase II double blind, randomized placebo-controlled study in Critical Limb Ischemia patients. The preliminary analyses suggest efficacy of HGF gene therapy among some of the endpoints. No critical safety issues have been shown in this study so far.

After further detailed data analyses are complete, AnGes will begin preparation for the Phase III clinical study in the US. AnGes has a global alliance with Daiichi Pharmaceutical Co. Ltd. to commercialize HGF Gene Therapy. Therefore, AnGes will take into consideration the decision of Daiichi Pharmaceutical Co. Ltd. to finalize the future development plan.